Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease

Annals of Hematology

Volumn 83, Issue 4, 2004, Pages 237-241

  Claviez, Alexander ^a   Klingebiel, Thomas ^b   Beyer, Jörg ^c   Nürnberger, Wenzel ^d   Ehninger, Gerhard ^e   Suttorp, Meinolf ^e   Dreger, Peter ^f   Dörffel, Wolfgang ^g   Schmitz, Norbert ^f  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c PHILIPPS UNIVERSITY MARBURG   (Germany)

^d Clinic for Bone Marrow Transplantation and Hematology/Oncology   (Germany)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f DEPARTMENT OF CARDIOLOGY   (Germany)

^g 2nd Children's Hospital   (Germany)

Author keywords

Advanced Hodgkin's disease; Allogeneic peripheral blood stem cell transplantation; Children; Fludarabine based conditioning

Indexed keywords

BLEOMYCIN; BUSULFAN; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; IFOSFAMIDE; LYMPHOCYTE ANTIBODY; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; PROCARBAZINE; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; VINBLASTINE;

ADOLESCENT; ADULT; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DONOR; DRUG WITHDRAWAL; FEMALE; GRAFT VERSUS HOST REACTION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE TRANSFUSION; MALE; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SALVAGE THERAPY; SCHOOL CHILD; SURVIVAL TIME; TREATMENT FAILURE; TUMOR RECURRENCE; TUMOR REGRESSION;

ADOLESCENT; ANTINEOPLASTIC AGENTS; BUSULFAN; CHILD; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HODGKIN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MELPHALAN; NEOPLASM RECURRENCE, LOCAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; VIDARABINE;

EID: 1842529554     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-003-0814-y     Document Type: Article

References (15)

1. Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, Zahurak ML, Fuller D, Miller CB, Noga SJ, Fuchs E, Flinn IW, O'Donnell P, Seifter EJ, Mann RB, Jones RJ (2001) Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 19:4314-4321
2. Anderlini P, Giralt S, Andersson B, Ueno NT, Khouri I, Acholonu S, Cohen A, Korbling MJ, Manning J, Romaguera J, Sarris A, Rodriguez MA, Hagemeister F, Mclaughlin P, Cabanillas F, Champlin RE (2000) Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease. Bone Marrow Transplant 26:615-620
3. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD, Petersen FB, Crawford SW, Press OW, Sanders JE, Bensinger WI, Martin PJ, Storb R, Sullivan KM, Hansen JA, Thomas ED (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 11:2342-2350
4. Carella AM, Cavaliere M, Lerma E, Ferrara R, Tedeschi L, Romanelli A, Vinci M, Pinotti G, Lambelet P, Loni C, Verdiani S, De Stefano F, Valbonesi M, Corsetti MT (2000) Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stemcell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 18:3918-3924
5. Claviez A, Boogaerts MA, Slavin S, Pession A, Bosi A, Carella AM, Izzi T, Schmitz N (2002) Allogeneic hematopoietic stem cell transplantation in children and adolescents with Hodgkin's disease: An EBMT analysis. Bone Marrow Transplant 29 [Suppl 2]:10a
6. Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Lucesole M, Dodero A, Ciceri F, Benedetti F, Rambaldi A, Sajeva MR, Tresoldi M, Pileri A, Bordignon C, Bregni M (2002) Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 99:75-82
7. Dann EJ, Daugherty CK, Larson RA (1997) Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 20:369-374
8. Dörffel W, Lüders H, Rühl U, Albrecht M, Marciniak H, Parwaresch R, Pötter R, Schellong G, Schwarze EW, Wickmann L (2003) Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: Analysis and outlook. Klin Pädiatr 215:139-145
9. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP, Lazarus HM, McCarthy PL Jr, Pavlovsky S, Peterson FB, Rowlings PA, Russell JA, Silver SM, Vose JM, Wiernik PH, Bortin MM, Horowitz MM (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 14:572-578
10. Jones RJ, Ambinder RF, Piantadosi S, Santos GW (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649-653
11. Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JC, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S (2000) In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. Blood 96:2419-2425
12. Laurence AD, Goldstone AH (1999) High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma. Semin Hematol 36:303-312
13. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14:1291-1296
14. Robinson SP, Goldstone AH, Mackinnon S, Carella A, Russell N, Ruiz de Elvira C, Taghipour G, Schmitz N (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: An analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100:4310-4316
15. Schellong G, Pötter R, Brämswig J, Wagner W, Prott FJ, Dörffel W, Körholz D, Mann G, Rath B, Reiter A, Weissbach G, Riepenhausen M, Tiemann M, Schwarze EW (1999) High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 17:3736-3744